Correspondence 0001104659-23-036168 from SHL TELEMEDICINE LTD (SHLT) (CIK 0001166834) (SHMLF)
SHL TELEMEDICINE LTD (SHLT) (CIK 0001166834)
Date: March 23, 2023 · CIK: 0001166834 · Accession: 0001104659-23-036168
AI Filing Summary & Sentiment
File numbers found in text: 001-41641
Referenced dates: March 20, 2023
Letter
Norton Rose Fulbright US LLP
1301 Avenue of the Americas
New York, NY 10019-6022 United States
Direct line +1 212-318-3151
Scott.Saks@nortonrosefulbright.com
Tel +1 212 318 3000
Fax +1 212 408 5100
nortonrosefulbright.com
March 23, 2023
FILED VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Industrial Applications and Services
100 F Street, N.E.
Washington, D.C. 20549
Attention: Benjamin Richie
Lauren Nguyen
Re: SHL Telemedicine Ltd.
Amendment No. 1 to Registration Statement on
Form 20FR12B (File No. 001-41641)
Filed March 23, 2023
Ladies and Gentlemen:
On behalf of SHL Telemedicine Ltd. (the “Company”), we are responding to the remaining comment of the staff (the “Staff”) of the U.S. Securities and Exchange Commission (the “Commission”) conveyed in the Staff’s Comment Letter, dated March 20, 2023 (the “Comment Letter”), with respect to the Company’s Registration Statement on Form 20-FR12B (the “20-F”) publicly filed with the Commission by the Company via EDGAR on March 8, 2023. Concurrently with this response letter, the Company is publicly filing with the Commission via EDGAR Amendment No. 1 to its Registration Statement on Form 20-FR12B (“Amendment No. 1”), which has been revised to reflect the Company’s response to the remaining Staff comment.
For ease of review, we have set forth the Staff’s remaining comment below in bold italics type followed by the Company’s responses thereto. Page references in the Staff’s comment are to the page numbers contained in the Comment Letter. Page references in the Company’s response below correspond to the page numbers in Amendment No. 1.
United States Securities and Exchange Commission
March 23, 2023
Page 2
Overview, page 23
1. We note your response to our prior comment number 1 and your revision to page 26, where you state that you “have successfully proven through several clinical studies that users of the SHL’s mobile 12 lead ECG technology benefit from a lower risk of being re-hospitalized during the first 30 days and a lower risk of mortality during the first year following discharge from the hospital after a heart attack and an improvement in quality of life.” As efficacy determinations are solely within the FDA’s authority, please revise these references to SHL technology’s proven efficacy. You may provide relevant quantitative data from the studies to support your claims.
Response: The Company respectfully acknowledges and has complied with the Staff’s comment by revising the references to proven efficacy and providing quantitative data from the clinical studies, together with details of the clinical studies, on page 25 in Amendment No. 1.
* * *
We hope that the foregoing response and corresponding revisions contained in the Amendment No. 1 are responsive to the Staff’s comment. Please do not hesitate to contact the undersigned, Scott R. Saks, of Norton Rose Fulbright US LLP, counsel to the Company, at (212) 318-3151 or at scott.saks@nortonrosefulbright.com, or my partner, Sheldon G. Nussbaum, at (212) 318-3254 or at sheldon.nussbaum@nortonrosefulbright.com with any questions or comments or if you require any further information or it would otherwise facilitate the Staff’s review.
Very Truly Yours
By:
/s/ Scott R. Saks
Show Raw Text
CORRESP
1
filename1.htm
Norton Rose Fulbright US LLP
1301 Avenue of the Americas
New York, NY 10019-6022 United States
Direct line +1 212-318-3151
Scott.Saks@nortonrosefulbright.com
Tel +1 212 318 3000
Fax +1 212 408 5100
nortonrosefulbright.com
March 23, 2023
FILED VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Industrial Applications and Services
100 F Street, N.E.
Washington, D.C. 20549
Attention:
Benjamin Richie
Lauren Nguyen
Re: SHL Telemedicine Ltd.
Amendment No.
1 to Registration Statement on
Form 20FR12B
(File No. 001-41641)
Filed March
23, 2023
Ladies and Gentlemen:
On behalf of SHL Telemedicine
Ltd. (the “Company”), we are responding to the remaining comment of the staff (the “Staff”) of the
U.S. Securities and Exchange Commission (the “Commission”) conveyed in the Staff’s Comment Letter, dated March
20, 2023 (the “Comment Letter”), with respect to the Company’s Registration Statement on Form 20-FR12B (the “20-F”)
publicly filed with the Commission by the Company via EDGAR on March 8, 2023. Concurrently with this response letter, the Company is publicly
filing with the Commission via EDGAR Amendment No. 1 to its Registration Statement on Form 20-FR12B (“Amendment No. 1”),
which has been revised to reflect the Company’s response to the remaining Staff comment.
For ease of review, we have
set forth the Staff’s remaining comment below in bold italics type followed by the Company’s responses thereto. Page references
in the Staff’s comment are to the page numbers contained in the Comment Letter. Page references in the Company’s response
below correspond to the page numbers in Amendment No. 1.
United States Securities and Exchange Commission
March 23, 2023
Page 2
Overview, page 23
1. We note your response to our prior comment number 1 and your revision to page 26, where you state
that you “have successfully proven through several clinical studies that users of the SHL’s mobile 12 lead ECG technology
benefit from a lower risk of being re-hospitalized during the first 30 days and a lower risk of mortality during the first
year following discharge from the hospital after a heart attack and an improvement in quality of life.” As efficacy determinations
are solely within the FDA’s authority, please revise these references to SHL technology’s proven efficacy. You may provide
relevant quantitative data from the studies to support your claims.
Response: The Company respectfully acknowledges and has complied with the Staff’s comment by revising the references to proven efficacy and providing
quantitative data from the clinical studies, together with details of the clinical studies, on page 25 in Amendment No. 1.
* * *
We hope that the foregoing response and corresponding
revisions contained in the Amendment No. 1 are responsive to the Staff’s comment. Please do not hesitate to contact the undersigned,
Scott R. Saks, of Norton Rose Fulbright US LLP, counsel to the Company, at (212) 318-3151 or at scott.saks@nortonrosefulbright.com,
or my partner, Sheldon G. Nussbaum, at (212) 318-3254 or at sheldon.nussbaum@nortonrosefulbright.com with any questions or comments
or if you require any further information or it would otherwise facilitate the Staff’s review.
Very Truly Yours
By:
/s/ Scott R. Saks
Scott R. Saks
cc: Erez Nachtomy (SHL Telemedicine Ltd.)
Amir Hai (SHL Telemedicine
Ltd.)
Sheldon G. Nussbaum
(Norton Rose Fulbright US LLP)
Amelia Zhang (Norton
Rose Fulbright US LLP)
Norton Rose Fulbright
US LLP is a limited liability partnership registered under the laws of Texas.
Norton Rose Fulbright
US LLP, Norton Rose Fulbright LLP, Norton Rose Fulbright Australia, Norton Rose Fulbright Canada LLP and Norton Rose Fulbright South
Africa Inc are separate legal entities and all of them are members of Norton Rose Fulbright Verein, a Swiss verein. Norton Rose Fulbright
Verein helps coordinate the activities of the members but does not itself provide legal services to clients. Details of each entity,
with certain regulatory information, are available at nortonrosefulbright.com.